A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. [electronic resource]
Producer: 20140514Description: 2601-2606 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Antineoplastic Agents, Phytogenic -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Apoptosis -- drug effects
- Carboplatin -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Disease-Free Survival
- Female
- Humans
- Imidazoles -- adverse effects
- Inhibitor of Apoptosis Proteins -- antagonists & inhibitors
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Naphthoquinones -- adverse effects
- Paclitaxel -- adverse effects
- Survival
- Survivin
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
There are no comments on this title.
Log in to your account to post a comment.